Table 4.
3GCR Enterobacteriaceae Antibiotic Susceptibilities
| 3GCR Isolate | Identification | Cipro | TMP-SMX | Gent | Cefepime | Pip-Tazo | Mero | ESBL | MDR |
|---|---|---|---|---|---|---|---|---|---|
| OAK1 | E coli | R | R | R | S | S | S | Y | Y |
| OAK2 | E coli | R | R | R | I | I | S | Y | Y |
| OAK3 | E coli | R | R | R | S | S | S | Y | Y |
| OAK4 | E coli | R | R | S | S | S | S | Y | Y |
| OAK5 | E coli | R | R | S | S | S | S | Y | Y |
| OAK6 | E coli | R | R | S | S | S | S | Y | Y |
| KC1 | E coli | S | S | S | S | R | S | N | N |
| KC2 | E coli | S | R | S | S | S | S | N | N |
| KC3 | E coli | S | S | S | S | S | S | Y | N |
| KC4 | E coli | R | R | S | S | S | S | N | Y |
| KC5 | E coli | S | R | S | S | S | S | Y | N |
| KC6 | E coli | S | R | R | I | I | S | Y | Y |
| KC7 | E coli | R | R | S | I | S | S | Y | Y |
| KC8 | E coli | S | R | S | S | S | S | Y | N |
| KC9 | E coli | R | S | S | S | S | S | Y | N |
| NASH1 | E coli | R | S | R | I | S | S | Y | Y |
| NASH2 | E coli | S | S | S | S | I | S | N | N |
| NASH3aa | E coli | R | R | R | S | I | S | Y | Y |
| NASH3ba | E coli | R | R | R | I | S | I | Y | Y |
| NASH4 | E coli | R | R | S | S | S | S | Y | Y |
| NASH5 | E coli | S | R | S | I | S | S | Y | N |
| NASH6 | E coli | S | R | S | I | S | S | Y | N |
| NASH7 | E coli | R | R | R | I | I | S | Y | Y |
| NASH8 | K pneumoniae | S | R | S | R | S | S | N | N |
| Nonsusceptible, ESBL-P, or MDR rate (%) | 58 | 79 | 33 | 38 | 25 | 4 | 79 | 58 |
Abbreviations: 3GCR, third-generation cephalosporin resistant; Cipro, ciprofloxacin; ESBL-P, extended-spectrum β-lactamase producing (confirmed by double-disk diffusion testing); Gent, gentamicin; I, intermediate; KC, Kansas City; MDR, multidrug resistant (defined as nonsusceptible to ≥1 agent in ≥3 antimicrobial classes); Mero, meropenem; N, no; NASH, Nashville; OAK, Oakland; Pip-Tazo, piperacillin-tazobactam; R, resistant; S, susceptible; TMP-SMX, trimethoprim-sulfamethoxazole; Y, yes.
a
From the same subject.